• 1
    Ginsberg JP, Woo SY, Johnson ME, et al. Ewing sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: PizzoPA, PoplackDG, editors. Principles and practice of pediatric oncology ( 4th edition). Philadelphia: Lippincott-Raven, 2002: 9731016.
  • 2
    Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors—a subgroup of small round cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994; 331: 294299.
  • 3
    Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994; 6: 146151.
  • 4
    Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995; 10: 12291234.
  • 5
    Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETS-family gene, E1AF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer. 1996; 15: 115121.
  • 6
    Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997; 14: 11591164.
  • 7
    Ginzberg JP, de Alava E, Ladanyi M, et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol. 1999; 17: 18091814.
  • 8
    Naito N, Kawai A, Ouchida M, et al. A reverse transcriptase polymerase chain reaction assay in the diagnosis of soft tissue sarcomas. Cancer. 2000; 89: 19921998.
  • 9
    Zoubek A, Pfleiderer C, Salzer-Kuntschik M, et al. Variability of EWS chimeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer. 1994; 70: 908913.
  • 10
    Pfleiderer C, Zoubek A, Gruber B, et al. Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. Int J Cancer. 1995; 64: 135139.
  • 11
    Peter M, Magdelenat H, Michon J, et al. Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer. 1995; 72: 96100.
  • 12
    West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol. 1997; 15: 583588.
  • 13
    Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer. 1998; 79: 5660.
  • 14
    Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. J Clin Oncol. 1998; 16: 17071711.
  • 15
    Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol. 2003; 21: 8591.
  • 16
    de Alava E, Lozano MD, Patino A, Sierrasesumaga L, Pardo-Mindan FJ. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol. 1998; 7: 152157.
  • 17
    Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993; 12: 44814487.
  • 18
    Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol. 1996; 14: 12451251.
  • 19
    de Alava E, Kawai A, Healy JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998; 16: 12481255.
  • 20
    van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352: 17311738.
  • 21
    Biondi A, Valsecchi MG, Seriu T, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM Study Group. Leukemia. 2000; 14: 19391943.